|
121 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2334 News |
|
| «12...2728293031323334353637...4647» |
- Trial completion: Blood-brain Barrier Permeability in Alzheimer's Disease (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=39, Completed, Sponsor: Maastricht University Medical Center
Recruiting --> Completed
- |||||||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
New P3 trial: STARBRIGHT: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (clinicaltrials.gov) - Dec 8, 2013
P3, N=720, Recruiting, Sponsor: H. Lundbeck A/S
- |||||||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
New P3 trial: STARBEAM: Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Dec 8, 2013
P3, N=840, Recruiting, Sponsor: H. Lundbeck A/S
- | ABT 354 / AbbVie
Trial completion: Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors (clinicaltrials.gov) - Dec 8, 2013
P1, N=20, Completed, Sponsor: AbbVie
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease (clinicaltrials.gov) - Dec 8, 2013
P2, N=40, Completed, Sponsor: University of Sao Paulo
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study) (clinicaltrials.gov) - Dec 5, 2013
P=N/A, N=16, Completed, Sponsor: University of Manitoba
Recruiting --> Completed N=20 --> 16
- ||| bradanicline (ATA-101) / CODA Biotherap
Enrollment change: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
N=20 --> 16 N=456 --> 603
- Trial completion: Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study) (clinicaltrials.gov) - Dec 5, 2013
P=N/A, N=16, Completed, Sponsor: University of Manitoba
N=456 --> 603 Recruiting --> Completed
- |||| bradanicline (ATA-101) / CODA Biotherap
Trial completion: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025 (clinicaltrials.gov) - Dec 5, 2013
P3, N=1000, Not yet recruiting, Sponsor: FORUM Pharmaceuticals Inc
- ||||| rivastigmine transdermal / Generic mfg.
Enrollment closed: Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) (clinicaltrials.gov) - Dec 4, 2013
P3, N=101, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Cognitive Impairment Following Cardiac Arrest and Target Temperature Management (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=287, Completed, Sponsor: Region Skane
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open: The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly (clinicaltrials.gov) - Dec 2, 2013
P0, N=44, Recruiting, Sponsor: Tufts University
Recruiting --> Completed Not yet recruiting --> Recruiting
- GSK2647544 / GSK
Enrollment open: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Nov 26, 2013
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=100, Completed, Sponsor: University of Konstanz
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment open: SensiCare: Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=35, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Trial completion: A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Nov 24, 2013
P3, N=256, Completed, Sponsor: SK Chemicals Co.,Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers (clinicaltrials.gov) - Nov 24, 2013
P1, N=25, Completed, Sponsor: Bayer
Recruiting --> Completed N=54 --> 25
- |||||| verubecestat (MK-8931) / Merck (MSD)
Enrollment open: APECS: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (clinicaltrials.gov) - Nov 18, 2013
P3, N=1500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=54 --> 25 Not yet recruiting --> Recruiting
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Nov 18, 2013
P2, N=438, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| PF-05236812 / J&J, Pfizer
Trial completion: Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease (clinicaltrials.gov) - Nov 18, 2013
P1, N=88, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: VERVE: Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project (clinicaltrials.gov) - Nov 17, 2013
P=N/A, N=20, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: CROVCD: Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder (clinicaltrials.gov) - Nov 14, 2013
P=N/A, N=280, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | risperidone / Generic mfg., olanzapine / Generic mfg., quetiapine / Generic mfg.
Trial completion, Combination therapy, Monotherapy: A Comparison of Two Standard Therapies in the Management of Dementia With Agitation (clinicaltrials.gov) - Nov 11, 2013
P4, N=50, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Completed
- atorvastatin / Generic mfg.
Enrollment closed: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Nov 11, 2013
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC (clinicaltrials.gov) - Nov 7, 2013
P0, N=5, Completed, Sponsor: Institute for Neurodegenerative Disorders
Recruiting --> Active, not recruiting N=18 --> 5
- Enrollment change: Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (clinicaltrials.gov) - Nov 7, 2013
P1, N=11, Completed, Sponsor: Institute for Neurodegenerative Disorders
N=18 --> 5 N=27 --> 11
- Trial completion: Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC (clinicaltrials.gov) - Nov 7, 2013
P0, N=5, Completed, Sponsor: Institute for Neurodegenerative Disorders
N=27 --> 11 Recruiting --> Completed
- Trial completion: Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (clinicaltrials.gov) - Nov 7, 2013
P1, N=11, Completed, Sponsor: Institute for Neurodegenerative Disorders
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=66, Recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Nov 5, 2013
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
- | GSK2647544 / GSK
New P1 trial: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Nov 5, 2013
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
- AD03 / AFFiRiS
Trial termination: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A (clinicaltrials.gov) - Nov 4, 2013
P=N/A, N=16, Terminated, Sponsor: Affiris AG
Not yet recruiting --> Recruiting Enrolling by invitation --> Terminated; The study could not be performed as planned for organizational reasons.
- AD03 / AFFiRiS
Enrollment change: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A (clinicaltrials.gov) - Nov 4, 2013
P=N/A, N=16, Terminated, Sponsor: Affiris AG
Enrolling by invitation --> Terminated; The study could not be performed as planned for organizational reasons. N=24 --> 16
- |||| MK-7622 / Merck (MSD)
Enrollment open: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Nov 4, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=24 --> 16 Not yet recruiting --> Recruiting
- Enrollment closed: CogEx: Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis (clinicaltrials.gov) - Nov 3, 2013
P1/2, N=50, Active, not recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors (clinicaltrials.gov) - Nov 3, 2013
P2, N=434, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: FTDOXY10EF: Safety Study of Intranasal Oxytocin in Frontotemporal Dementia (clinicaltrials.gov) - Oct 31, 2013
P1, N=23, Completed, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: Memory Training in Patients With Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Oct 30, 2013
P=N/A, N=30, Recruiting, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: VENUS: Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 30, 2013
P4, N=300, Recruiting, Sponsor: University of Science Malaysia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Trial termination: Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) (clinicaltrials.gov) - Oct 29, 2013
P3, N=1121, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Not yet recruiting --> Recruiting Completed --> Terminated
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Trial termination: Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) (clinicaltrials.gov) - Oct 29, 2013
P3, N=1331, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Completed --> Terminated Completed --> Terminated
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Enrollment change: A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 29, 2013
P3, N=896, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Completed --> Terminated N=1350 --> 896
- bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Enrollment change: AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 29, 2013
P2, N=194, Terminated, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
N=1350 --> 896 N=40 --> 194
- | mitoglitazone (MSDC-0160) / Metabolic Solutions
Enrollment change: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 29, 2013
P2, N=29, Completed, Sponsor: Metabolic Solutions Development Company
N=40 --> 194 N=40 --> 29
- | mitoglitazone (MSDC-0160) / Metabolic Solutions
Trial completion: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 29, 2013
P2, N=29, Completed, Sponsor: Metabolic Solutions Development Company
N=40 --> 29 Active, not recruiting --> Completed
- || Trial initiation date: Effect of NeuroAD on the Cognitive Function of Alzheimer Patients (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=120, Recruiting, Sponsor: Neuronix Ltd
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Oct 2013
- || Enrollment change: Effect of NeuroAD on the Cognitive Function of Alzheimer Patients (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=120, Recruiting, Sponsor: Neuronix Ltd
Initiation date: Apr 2013 --> Oct 2013 N=18 --> 120
- ||| Enrollment open: Effect of NeuroAD on the Cognitive Function of Alzheimer Patients (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=120, Recruiting, Sponsor: Neuronix Ltd
N=18 --> 120 Not yet recruiting --> Recruiting
- Trial completion: Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline (clinicaltrials.gov) - Oct 27, 2013
P4, N=395, Completed, Sponsor: Nara Medical University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed